CONNECT WITH US
HealthTech

HealthTech

Brazil records first mpox death in 2026

Medical Xpress logo

Published on

Add as a preferred source on Google
Brazil records first mpox death in 2026

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Brazil has logged its first mpox death of 2026, but officials are not treating the surge in cases as an outbreak, according to a public health institute.

Brazil has recorded 1,009 confirmed infections with the virus this year, according to a report published Friday by the Fiocruz Institute, which is affiliated with the health ministry.

The death was in Rio de Janeiro, where positive cases between September and November doubled compared to those recorded during the rest of the year.

The government has stepped up surveillance measures and purchased 25,000 new doses of an mpox vaccine, but is not currently treating the rise in cases as an outbreak because the number remains "significantly lower than the historic peak experienced in 2022," Fiocruz said.

Mpox, which is caused by a virus from the same family as the smallpox virus, causes fever, muscle aches and large boil-like skin lesions, and can be deadly.

It can be transmitted to humans by animals but can also be passed between people through close physical contact.

In 2022 and 2024, the World Health Organization declared mpox a public health emergency of international concern due to its rapid spread in certain countries.

The majority of cases in Brazil this year have been recorded in Sao Paulo and Rio de Janeiro—two of the three most populous states in the country of 214 million people.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.